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Background: The 6-min walk distance (6MWD) is widely used to evaluate functional capacity in
patients with chronic obstructive pulmonary disease (COPD).
Aim: To examine predictors for longitudinal change in 6MWD including self-reported phys-
ical activity, smoking habits, body composition, exacerbations, comorbidity and lung func-
tion.
Methods: The cohort included 389 patients aged 44e75 years, with clinically stable COPD in
GOLD stages IIeIV. The follow-up time was 3 years. Measurements included 6MWD, spirom-
etry, fat and fat free mass index (FMI and FFMI), and assessment of physical activity, smok-
ing habits, comorbidities and exacerbations by questionnaires. Generalized estimating
equations (GEE) regression analyses were used to analyze predictors for the change
in 6MWD.
Results: There was a reduction in 6MWD from baseline to 3 years for patients in GOLD stages
III and IV (B Z 36 m, 95% CI Z 51 to 7, p Z 0.009 and B Z 79 m, CI Z 125 to 20,
p Z 0.007). The unadjusted GEE analysis demonstrated that baseline self-reported physical
activity level, forced expiratory volume in one second (FEV1), forced vital capacity, FFMI,
GOLD stages and age predicted change in 6MWD, but in the adjusted GEE analysis only
self-reported physical activity level (p Z 0.001) and FEV1 (p Z 0.019) predicted change
over time.vidence-Based Practice, Bergen University College, Pb. 7030, 5020 Bergen, Norway. Tel.: þ47 55 58 71
(B. Frisk).
3 Elsevier Ltd. All rights reserved.
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Physical activity and longitudinal change in 6MWD 87Conclusion: Patients in GOLD stage II maintained their functional capacity assessed by 6MWD
over 3 years, while it was significantly reduced for patients in GOLD stages III and IV. Level of
physical activity and FEV1 were predictors for longitudinal change in functional capacity.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Exercise intolerance is the main factor limiting participa-
tion in activities of daily living in patients having chronic
obstructive pulmonary disease (COPD) [1]. The degree of
exercise intolerance is related to disease severity and is a
result of complex interactions between ventilatory me-
chanical impairment, limitations of gas exchange, periph-
eral muscle function and symptoms [1,2]. Functional
capacity in COPD is most commonly measured with the 6-
min walk test (6MWT) and the distance walked in six mi-
nutes (6MWD) used as the primary outcome [3,4].
Improvement in the 6MWD has been demonstrated after
participation in a pulmonary rehabilitation program [5].
Physical training is a corner stone in rehabilitation programs
and improves aerobic capacity and health related quality of
life. [1] Maintaining the benefits requires continued training
which may be a challenge for these patients when outside
organized training programs. The improved functional ca-
pacity after a rehabilitation program has shown to be
transient and has declined 1e2 years after rehabilitation
[6].
The natural long-term changes in 6MWD in COPD pa-
tients, not recruited through a pulmonary rehabilitation
program or assessment for surgery, have been examined in
four previous studies, with follow-up times between one
and five years [7e10]. The mean annual decline in 6MWD
varied between 2 and 40 m per year [7e10]. In the Eclipse
study [10], the change in 6MWD was related to age, gender,
body mass index (BMI) and lung function by the Global
Initiative for Chronic Obstructive Lung Disease [11] (GOLD)
stage. The patients had no restriction receiving prescribed
medication or other therapies during the study period,
including rehabilitation, and such interventions were not
registered. The effect of habitual physical activity was not
assessed in any of these studies. The aim of the present
study was to examine predictors for the longitudinal change
in the 6MWD. We hypothesized that high habitual physical
activity is associated with a lower longitudinal decline in
6MWD, and included self-reported physical activity, lung
function, smoking habits, body composition, exacerbations
and comorbidity in the analysis.Methods
Study population
Of 433 patients with clinically stable COPD from the Bergen
COPD Cohort Study (2006e2010), 389 patients aged 44e75
years completed the 6MWT at baseline and were included in
the current study. The follow-up time was three years
(Fig. 1). Selection of the study population and the inclusionand exclusion criteria have been described in detail previ-
ously [12]. In brief, all patients were diagnosed with COPD,
had a smoking history of 10 pack years, a post-
bronchodilation forced expiratory volume in one second
(FEV1)/forced vital capacity (FVC) ratio <0.7 and a post-
bronchodilation FEV1 <80% of predicted value according
to Norwegian reference values [13]. Exacerbations that
required medical treatment during the last four weeks prior
to inclusion, led to deferment of inclusion. Patients with
inflammatory disorders like rheumatoid arthritis, systemic
lupus erythematosus or other connective tissue disorders,
inflammatory bowel disease, and any active cancer in the
last five years were excluded. Common chronic diseases
with known inflammatory components like chronic heart
disease, diabetes and hypertension were not a cause for
exclusion.
The Bergen COPD Cohort Study, in which the patients
were a subsample of the ECLIPSE study [14], made no re-
strictions to treatment in the study period, and the par-
ticipants were therefore free to receive medication and
therapies, including rehabilitation, prescribed by their
physician. In the Bergen COPD Cohort Study additional in-
formation on treatment and habitual physical activity dur-
ing the study period was registered, which was not part of
the ECLIPSE study. Of the 389 patients that completed
6MWT at baseline, 89 had participated in a pulmonary
rehabilitation program during the study period, all of them
within the first two years of the observation period. The
rehabilitation program lasted for 7 weeks, and consisted of
17 sessions, each lasting for about 5.5 h.
Ethics
The study was approved by the Western Norway Regional
Research Ethics Committee. Participation in the study was
voluntary. Written and oral information was given, and
written consent was obtained prior to the inclusion.
Assessment tools
Six-min walk test
The 6MWT [4] was performed at baseline and after one and
three years after inclusion in the study. The 6MWD was used
as the primary outcome measure of functional capacity.
The test was performed indoor, along a 30 m flat, straight
enclosed corridor, according to the American Thoracic So-
ciety (ATS) guidelines [3]. A trained technician supervised
the patients. The test was performed once each time, and a
practice 6MWT was not done. Oxygen saturation (SpO2) and
heart rate (HR) were measured before and at the end of the
test using a pulseoxymeter (NONIN Medical Inc., Plymouth,
MN). The patients graded their level of dyspnea and fatigue
by the Borg CR 10 scale [15] at the beginning and at the end
Figure 1 The study population during 3 years of follow-up. COPD: chronic obstructive pulmonary disease, 6MWT: six-min walk
test.
88 B. Frisk et al.of the test, and the 6MWD was registered. The use of ox-
ygen during the test was registered.
Self-reported physical activity
Self-reported physical activity was recorded at baseline
and after one and three years. There were two questions
related to spare time physical activity, one for light and
one for hard physical activity. The delineation between the
two was whether the activity resulted in breathlessness
and sweating or not. The response categories were none,
less than 1 h per week, 1e2 h per week and three or more
hours per week. These questions are validated [16,17] and
have been used in a large Norwegian general population
study [18].
Body composition, spirometry, dyspnea and Charlson
index for comorbidities
Height and body mass were measured. The patients un-
derwent bioelectrical impedance measurements of fat
mass and fat free mass (Bodystat 1500, Isle of Man, En-
gland) after an overnight fast. The body mass index (BMI)
was calculated as the body mass divided by the square of
height, the fat free mass index (FFMI) as the fat free mass
divided by the square of height, and the fat mass index
(FMI) as the fat mass divided by the square of height [19].
Spirometry, both pre- and post- inhalation of 0.4 mg sal-
butamol, was conducted on a Viasys Masterscope (Viasys,
Hoechberg, Germany). The spirometer was calibrated
twice daily with a 3-L calibration syringe. The modifiedMedical Research Council (mMRC) dyspnea scale [20] was
used to measure symptoms of dyspnea. Charlson index for
comorbidities was determined from the information regis-
tered by the physician during the clinical examination at
baseline [21].Statistics
Descriptive statistics were used to characterize the study
population (mean and standard deviation (SD) and
percent). Independent t-tests were used to compare
continuous variables and chi square-tests for categorical
variables across gender. Generalized estimating equations
(GEE) regression analyses [22] with robust standard errors
were used to identify potential predictors for the longitu-
dinal change in 6MWD per year. An unstructured working
correlation structure was applied to adjust for within-
patient correlation. Time was modeled as both a categori-
cal variable (baseline, year 1, and year 3) and a continuous
variable when longitudinal change in 6MWD was analyzed.
The variables examined at baseline were age, gender,
number of exacerbations 12 months prior to inclusion,
FEV1, FVC, FMI, FFMI, pack years, Charlson index for
comorbidities and self-reported physical activity. Contin-
uous predictor variables were centered at their mean
values to obtain interpretable regression coefficients: Age
at 64 years, FEV1 at 1.5 l, FVC at 3.3 l, and FMI at 8.4 kg/m
2,
FFMI at 17.0 kg/m2 and pack years at 40.9 pack years.
Table 1 Characteristics of the 389 COPD-patients at baseline.
Variables Total Female Male Sex. diff. p-value
Sex, n (%) 389 (100) 153 (39.3) 236 (60.7)
Age (years) 63.6  6.8 62.6  6.3 64.2  7.0 0.034
Smoking status n (%) 0.215
Current 167 (43.0) 72 (47.0) 95 (40.0)
Former 222 (57.0) 81 (53.0) 141 (60.0)
Pack years 40.9  22.8 33.4  16.5 45.5  25.0 <0.001
BMI (mean, kg/m2) 25.4  5.2 24.6  5.7 25.9  4.8 0.015
FMI (mean, kg/m2) 8.4  3.3 9.9  3.7 7.4  2.6 <0.001
FFMI (mean, kg/m2) 17.0  3.2 14.7  2.4 18.5  2.8 <0.001
FEV1 (l) 1.5  0.5 1.3  0.4 1.7  0.5 <0.001
FEV1 (% pred) 48.7  14.0 49.6  13.6 48.1  14.3 0.296
FVC (l) 3.3  0.9 2.7  0.6 3.7  0.8 <0.001
FVC (% pred) 85.2  16.6 85.2  17.1 85.6  16.4 0.791
FEV1/FVC (%) 45.7  11.1 47.7  11.0 44.5  11.0 0.008
GOLD category (%)
II n 179 (46) 77 (50) 102 (43)
III n 169 (43) 65 (42) 104 (44)
IV n 41 (11) 12 (8) 29 (12)
6MWD 423  112 405  104 435  116 0.009
SpO2
Before 6MWT 94  2.7 94  2.9 94  2.6 0.621
After 6MWT 91  5.7 91  6.1 91  5.4 0.804
Heart rate
Before 6MWT 86  14.8 89  14.7 85  14.7 0.013
After 6MWT 110  18.0 114  17.9 108  17.5 <0.001
Borg CR-10 dyspnea score (median)
Before 6MWT 0.5 1.5 0.3 0.050
After 6MWT 4.0 4.0 3.0 0.090
mMRC dyspnea grade 2.2  2.3 2.3  2.4 2.1  2.2 0.441
Experienceda 2 exacerbations last year (%)
No n 310 (81) 114 (75) 196 (84) 0.027
Yes n 75 (19) 38 (25) 37 (16)
Charlson comorbidity index (%) 0.011
1 225 (58) 99 (65) 126 (53)
2 93 (24) 38 (25) 55 (23)
3 46 (12) 12 (8) 34 (15)
4 25 (6) 4 (2) 21 (9)
Hard physical activity per week n (%) 0.117
No activity 146 (41) 64 (46) 82 (38)
<1 h 69 (19) 21 (15) 48 (22)
1e2 h 80 (23) 35 (25) 45 (21)
3 h> 61 (17) 19 (14) 42 (19)
Light physical activity per week n (%) 0.723
No activity 46 (13) 19 (13) 27 (12)
<1 h 51 (14) 18 (13) 33 (15)
1e2 h 107 (30) 46 (33) 61 (28)
3 h> 156 (43) 58 (41) 98 (45)
Data are presented as mean  SD, unless otherwise stated. BMI: body mass index; FMI: fat mass index; FFMI: fat free mass index; FEV1:
forced expiratory volume in one second; FVC: forced vital capacity; 6MWD: 6 min walking distance; mMRC: modified Medical Research
Council.
a Exacerbations requiring either hospitalization with oral antibiotics or oral steroids. Chi square for categorical variables and inde-
pendent t-test for continuous variables.
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and time were included to investigate the effects of these
variables on change in 6MWD during follow-up. For unad-
justed estimates, we calculated one GEE analysis for eachpredictor variable, which included the variable, time and
the interaction term of variable and time. For the adjusted
GEE analysis, we fitted a model where all the predictor
variables and time and the interaction terms of variable
Table 2 Participation in pulmonary rehabilitation as
predictor of hard physical activity at 3-years follow-up as
estimated by logistic regression.
Variable OR (95% CI) p-Value
Rehabilitation
No 1
Yes 2.42 (1.41, 4.15) 0.001
Sex
Female 1.00
Male 0.55 (0.22, 1.34) 0.186
Age 0.96 (0.93, 1.00) 0.047
FEV1 1.15 (0.59, 2.26) 0.678
FVC 1.05 (0.68, 1.62) 0.837
FFMI 1.11 (0.97, 1.27) 0.128
FMI 0.95 (0.85, 1.05) 0.312
Pack years 0.99 (0.98, 1.00) 0.037
Exacerbations last year 1.05 (0.84, 1.31) 0.672
Charlson comorbidity index
1 1
2 1.31 (0.74, 2.32) 0.356
3 1.14 (0.51, 2,57) 0.749
4 0.47 (0.15, 1.48) 0.199
Odds ratio (OR) and 95% confidence interval (CI) examined by
logistic regression in multivariate analyses (p < 0.05).
90 B. Frisk et al.and time were included in the model. Analysis for multi-
collinearity between FEV1 and FVC, and between FMI and
FFMI did not indicate multicollinearity, therefore all pre-
dictor variables, except GOLD stages were included in the
same analysis. A possible confounder could be participation
in rehabilitation during the study period. Separate GEE
analysis with adjustment for participation in rehabilitation
was done. In addition, we did separate GEE analysis for
patients who did and did not participate in rehabilitation
according to examine predictors for longitudinal change in
6MWD.
Multivariate logistic regression was applied to assess
predictors for physical activity at 3 years follow-up with
adjustment for participation in pulmonary rehabilitation
(yes/no), age, gender, number of exacerbations 12 months
prior to inclusion FEV1, FVC, FMI, FFMI, pack years and
Charlson index for comorbidities.
Self-reported light and hard physical activity had four
possible response categories, but in the GEE analysis and in
the multivariate logistic regression, we transformed it to
two response categories for both light and hard physical
activity (no activity/light physical activity and no activity/
hard physical activity).
Estimated regression coefficients are presented with 95%
confidence intervals (CI) and p-values. The significance
level was set at 0.05. The data analyses were performed
using IBM SPSS Statistics 20 (SPSS Inc. Chicago, Illinois,
USA).
Results
Of the 389 patients who completed the baseline 6MWT, 319
(82%) and 264 (68%) completed the test at year 1 and 3
respectively (Fig. 1). At baseline, 13 (3.3%) patients used
oxygen during the 6MWT, and at 1 and 3 years follow-up 11
(3.4%) and 10 (3.8%) did so. Baseline characteristics of the
population are presented in Table 1. The patients’ mean
age was 64  7 years, 61% were males and mean FEV1 in
percent of predicted value was 49  14%. According to
GOLD stage, 179 (46%) patients were in stage II, 169 (43%) in
stage III, and 41 (11%) in stage IV.
There was no significant difference in baseline charac-
teristics, including 6MWD, between patients participating
in pulmonary rehabilitation during the study period and
non-participants. The dropout rates were 10% and 20%, and
20% and 36% at 1 and 3 years follow-up in those who did and
did not participate in rehabilitation respectively. The
fraction of subjects performing hard physical activity at
three years was higher in those who had participated in a
rehabilitation program, odds ratio 2.4 (95% CI 1.4e4.2,
p Z 0.001) (Table 2).
Longitudinal change in 6MWD
There were no differences in effort during the 6MWTs. The
adjusted GEE analysis showed that the differences in SpO2,
HR and Borg score between measurements immediately
before and immediately after the 6MWT were not signifi-
cantly different at any time.
The distribution of the individual change in 6MWD from
baseline to 3 years is shown in Fig. 2. The median reductionwas 16 m. Estimated unadjusted mean 6MWD at baseline
and after 1 and 3 years was 423 (95% CI: 412e434), 431 (95%
CI: 419e433) and 400 (95% CI: 385e415) meters, respec-
tively. The decrease in 6MWD from baseline to 3 years was
statistically significant (B Z 23, 95% CI: 34 to 12,
p < 0.001). The decrease over time in 6MWD was only
evident for patients in GOLD stage III (BZ 36, 95% CI: 51
to 7, pZ 0.009) and in GOLD stage IV (BZ 79 m, 95% CI:
125 to 20, p Z 0.007) (Fig. 3).
Predictors for longitudinal change in 6MWD
The unadjusted GEE analysis demonstrated that baseline
habitual hard physical activity, FEV1, FVC, GOLD stage,
FFMI and age were predictors for change in 6MWD, but in
the adjusted GEE analysis only hard physical activity and
FEV1 predicted change in 6MWD. Yearly change in 6MWD for
performing regular hard physical activity was positive,
3.9 m per year (p Z 0.001), and for FEV1 it was positive,
12.4 m per year per liter increase in FEV1 (p Z 0.019)
(Table 3). When excluding patients who used oxygen during
the 6MWT, the results from the adjusted GEE analysis was
the same as when all the patients were included in the
analysis. When separate GEE analyses were done for pa-
tients who did and did not participate in rehabilitation,
hard physical activity and FEV1 remained as significant
predictors for change in 6MWD.
Discussion
The main findings of the study were 1) Patients in GOLD
stage II maintained their 6MWD during the follow-up period
of 3 years, while it was significantly reduced in patients in
Figure 2 The distribution of the change in the six-min walk distance (6MWD), 3 years minus baseline.
Physical activity and longitudinal change in 6MWD 91GOLD stages III and IV. 2) The predictors at baseline for
longitudinal change in 6MWD were self-reported hard
physical activity and FEV1. 3) Patients that had partici-
pated in a pulmonary rehabilitation program during theFigure 3 Mean six-min walk distance (6MWD) by GOLD-stages
estimated with unadjusted generalized estimating equations
(GEE) regression analyses during 3 years of follow-up.study period reported a higher physical activity level at 3
years.
In normal subjects and in patients with mild COPD the
6MWD is biomechanically limited by their maximal walking
speed rather than by their ventilatory capacity. This could
be a reason why the patients in GOLD stage II maintained
their 6MWD over 3 years. Some of the COPD patients had a
6MWD not different from the normal population. Both
Casanova et al. [7] and Spruit et al. [10] demonstrated that
6MWD declined over time, but this finding was only signifi-
cant in patients with severe airflow limitation. Even though
there was a decline in 6MWD in our study for patients in
GOLD stage III and IV, and the other follow-up studies
[7,9,10], the mean annual change in 6MWD was less than
the minimal clinically important change that has been
estimated to be 54 m. [23]. The patients in our study were a
subsample of the larger ECLIPSE study. The results with
respect to the longitudinal change in 6MWD were consistent
[10]. However, Kapella et al. [8] found the 6MWD to be
stable during a follow-up period of three years.
To our knowledge, this is the first study to report that
physical activity was a significant predictor for change in
6MWD. The analyses showed that reporting hard physical
activity at baseline influenced the longitudinal change in
6MWD positively. At 3 years follow-up, the fraction of
subjects reporting regular hard physical activity was higher
compared to baseline, and patients who had participated in
pulmonary rehabilitation during the study period did so
Table 3 Unadjusted and adjusted yearly change in 6-
min walk distance (6MWD) for baseline predictor variables,
estimated by general estimating equations (GEE) analysis.
Predictors at
baseline
Unadjusted Adjusted*
Yearly
change
in 6MWD
p-Value Yearly
change
in 6MWD
p-Value
Sex
Women 14.3 13.1
Men 9.6 0.316 15.8 0.694
Age
at 64 years 12.7 13.1
per 10 years
increase
5.3 0.042 0.6 0.816
GOLD stage
II 45.5
III 14.1 0.048
IV 34.7 0.006
FEV1
at 1.5 l 11.7 13.1
per liter
increase
14.8 <0.001 12.4 0.019
FVC
at 3.3 l 11.8 13.1
per liter
increase
7.3 0.001 0.2 0.957
FFMI
at 17.0 kg/m2 11.7 13.1
per kg/m2
increase
1.4 0.046 0.4 0.692
FMI
at 8.4 kg/m2 11.9 13.1
per kg/m2
increase
0.11 0.886 0.1 0.881
Pack years
at 40.9 years 11.5 13.1
per 10 years
increase
0.4 0.620 0.2 0.844
Exacerbations last yeara
0e1 9.8 13.1
2 18.2 0.159 14.6 0.772
Charlson comorbidity index
1 9.9 13.1
2 17.4 0.180 21.7 0.070
3 6.0 0.538 6.3 0.214
4 20.3 0.282 19.2 0.423
Hard physical activity
No activity 22.5 0.002 13.1
Hard activity 6.1 3.9 0.001
Light physical activity
No activity 16.2 0.564 13.1
Light activity 11.1 21.1 0.348
*In the adjusted GEE analysis all the predictor variables, time
and the interaction terms between the variable and time were
included in the analysis. FEV1: forced expiratory volume in one
second; FVC: forced vital capacity; FFMI: fat free mass index;
FMI: fat mass index.
a Exacerbations requiring either hospitalization with oral an-
tibiotics or oral steroids last year prior to inclusion.
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improve the FEV1 [24], but it does improve skeletal-muscle
function and endurance [24]. Dynamic hyperinflation has
been demonstrated to be reduced when exercising regu-
larly, which leads to mitigation in dyspnea [25]. High in-
tensity training at an intensity of at least 60% of maximal
exercise tolerance is necessary to achieve improvements in
physical performance [1]. Our results demonstrated that
only subjects reporting hard physical activity had an effect
on the 6MWD.
The activity in our study was self-reported and thereby
subject to bias by overestimation. The correlation between
physical activity reported by questionnaire and objectively
assessed activity by accelerometer has been shown to be
weak [26]. However, a moderate correlation between self-
reported physical activity and 6MWD was demonstrated by
Walker et al. [26] and Nguyen et al. [27] Troosters et al.
[28] measured physical activity objectively with an activity
monitor for a period of 5e7 days in a group of cystic fibrosis
patients. Moderate physical activity was related to peak
oxygen uptake and quadriceps force, but not to 6MWD.
Activity monitors are more accurate than self-reported
questionnaire, but monitoring is usually done for shorter
periods only, and awareness of the ongoing monitoring may
increase activity level above the habitual. Rehabilitation
may have a similar effect on awareness with respect to
physical activity. Rehabilitation took place in the first year
of the observation period for most patients. The effect of
rehabilitation wanes over time [6], and such an effect will
probably be small at 3 years.
FEV1 was the other significant predictor for change in
6MWD. Spruit et al. [10] found that age and baseline body
weight predicted change in 6MWD, while there was a
differential effect of GOLD stage. We could not find that
age and body mass index influenced the longitudinal
change in 6MWD. GOLD stages are related to FEV1, which
was a significant predictor in our study. Ventilatory ca-
pacity is related to maximal expiratory flow rates and
FEV1, and ventilatory capacity will at some point be the
limiting factor for exercise performance. It is reasonable
then, to find an association between 6MWD and FEV1.
There is an association between maximal exercise tests
and walking tests [29,30] like the 6MWT and the Shuttle
walk test [31] in COPD patients, and reduced maximal and
functional exercise tests are both related to reduced
ventilatory capacity.Methodological considerations
The Bergen COPD-cohort study excluded patients with in-
flammatory disorders like rheumatoid arthritis, while pa-
tients with common chronic diseases with known
inflammatory components like chronic heart disease, dia-
betes and hypertension were included in the study. The
comorbidity could be thought to influence the longitudinal
change in 6MWD. However, comorbidity was not a predictor
of change in 6MWD. In a general COPD population, espe-
cially among patients in GOLD stages III or IV, other chronic
diseases are common. We assume that our study population
is representative for the common COPD patients met in
outpatient clinics or in hospitals.
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formed once on each occasion in our study, even though
two tests are recommended according to ATS guidelines
[3]. The learning effect is a bias in the 6MWT and to reduce
it, two tests are preferred [3]. In the study of Hernandes
et al. [32] the learning effect between first and second
test resulted in an increase in 6MWD of 27 m. The tests
were performed on two consecutive days. Our subjects
increased their 6MWD from baseline to 1 year. It is possible
that a learning effect could hide a natural decline in the
6MWD over this period, but it is more unlikely that the
effect could last for 3 years. The changes in SpO2, HR and
Borg score were not different from baseline to 1 year or
from baseline to 3 years for any GOLD stages. This could
indicate that the patients’ effort was the same at base-
line, 1-year and 3 years follow-up.
Study population
Among patients included in the study, the distribution ac-
cording to GOLD stages were 179 patients in GOLD stage II,
169 in stage III and 41 in stage IV. There were fewer patients
with more serious disease state as represented by GOLD
stage IV. The explanation might be that the most severely
ill patients were not able to participate in the study
because of limited functional capacity. This finding is
similar to other studies [8,10]. However, the majority of our
patients were in GOLD stages III and IV. The dropout rate
from baseline to 3 years was 32%. The patients were lost to
follow-up mostly because of death or increased disease
severity. Kapella et al. [8] and Spruit et al. [10] also had a
study period of 3 years and the dropout rates in these
studies were 31%. Casanova et al. [7] had a follow-up period
of 5 years, and the dropouts during the study period was
34%. COPD is a progressive disease and in long-term studies,
an increasing dropout rate is unavoidable. In this respect,
our results are in accordance with previous studies. The
dropout rate was higher in those who did not participate in
pulmonary rehabilitation. The explanation is probably that
the most severely ill patients were not able to participate
in pulmonary rehabilitation.
Conclusion
Our findings demonstrated that patients in GOLD stage II
maintained their functional capacity assessed by 6MWD
over 3 years, while it was significantly reduced for patients
in GOLD stages III and IV. Level of habitual physical activity
and FEV1 were predictors for longitudinal change in func-
tional capacity. The level of physical activity was higher at
three years in subjects who had participated in a rehabili-
tation program during the observation period. The pre-
vention of further reduction in lung function, if possible,
and implementation of physical training programs seem to
be important for maintaining functional capacity over time
in COPD patients.
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